Glucagon
Also known as: Baqsimi · Ogluo · Glucagon 1555
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
In short
In the European Union, glucagon products are indicated for the treatment of severe hypoglycaemia in patients with diabetes mellitus, specifically for adults, adolescents, and children aged 4 years and over for Baqsimi, and aged 2 years and over for Ogluo. In the United States, Glucagon for Injection is indicated as an antihypoglycemic agent for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus. Additionally, in the United States, Glucagon for Injection is indicated as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.
From: Source: European Medicines Agency (EMA), Baqsimi — EPAR, 15/09/2025. © European Medicines Agency. · Source: European Medicines Agency (EMA), Ogluo — EPAR, 17/09/2025. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration.
AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.
Codes
- RxNorm
- 4832 glucagon
- EMA
- EMEA/H/C/003848, EMEA/H/C/005391
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
EMA (EU) Baqsimi
Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
Source: European Medicines Agency (EMA), Baqsimi — EPAR, 15/09/2025. © European Medicines Agency.
Document date: 15/09/2025 · Official document →
FDA (USA) Glucagon
1 INDICATIONS AND USAGE GLUCAGON for Injection is an antihypoglycemic agent and a gastrointestinal motility inhibitor indicated: for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes. ( 1.1 ) as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. ( 1.2 ) 1.1 Severe Hypoglycemia Glucagon for Injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus. 1.2 Diagnostic Aid Glucagon for Injection is indicated as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.
Data provided by the U.S. Food and Drug Administration.
Document date: 20260811 · Official document →
EMA (EU) Ogluo
Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
Source: European Medicines Agency (EMA), Ogluo — EPAR, 17/09/2025. © European Medicines Agency.
Document date: 17/09/2025 · Official document →
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Glucagon approved for in the European Union?
Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus. (Source: European Medicines Agency (EMA), Baqsimi — EPAR, 15/09/2025. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Data provided by the U.S. Food and Drug Administration.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Baqsimi — EPAR, 15/09/2025. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Ogluo — EPAR, 17/09/2025. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.